Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Full Year 2023 and Fourth Quarter (Q4) 2023, filed January 31, 2024.
Overview: GSK reported strong 2023 performance driven by broad-based growth in Vaccines and Specialty Medicines, offset by declines in General Medicines and the phase-out of COVID-19 solutions. The company upgraded its long-term growth outlooks for 2026 and 2031.
Key Financial Metrics
| Metric | 2023 Full Year (£m) | 2023 Growth (CER%) | Q4 2023 (£m) | Q4 2023 Growth (CER%) |
|---|---|---|---|---|
| Turnover | 30,328 | +5% | 8,052 | +15% |
| Turnover ex COVID | 30,134 | +14% | 8,032 | +17% |
| Total Operating Profit | 6,745 | +10% | 573 | -60% |
| Adjusted Operating Profit | 8,786 | +12% | 1,752 | +21% |
| Adjusted Operating Margin | 29.0% | +1.8 ppts | 21.8% | +1.2 ppts |
| Total Continuing EPS | 121.6p | +16% | 8.6p | -68% |
| Adjusted EPS | 155.1p | +16% | 28.9p | +25% |
| Cash Generated from Operations | 8,096 | +2% | 3,681 | +75% |
| Free Cash Flow | 3,409 | +2% | 2,095 | >100% |
| Net Debt | 15,040 | -12.5% | 15,040 | -12.5% |
Material Changes vs. Prior Period
- Revenue Growth: Total sales grew 5% (CER) in 2023, driven by Vaccines (+25%) and Specialty Medicines (+15% ex COVID). General Medicines grew 5% (CER) but declined 8% in Q4 due to generic erosion and RAR adjustments.
- Profitability: Adjusted operating profit grew 12% (CER) in 2023. Q4 Total Operating Profit declined 60% (CER) due to significant one-off charges, though Adjusted Operating Profit grew 21% (CER).
- Product Performance:
- Vaccines: Shingrix sales reached £3.4 billion (+17% CER); Arexvy (RSV) generated £1.2 billion in its first full year.
- Specialty Medicines: HIV sales grew 13% (CER) driven by Dovato and long-acting injectables (Cabenuva, Apretude). Oncology sales grew 23% (CER) led by Jemperli and Zejula.
- COVID-19 Solutions: Sales of Xevudy and pandemic vaccines declined significantly, impacting full-year growth by 4 percentage points.
- One-off Items: Q4 2023 included a £430 million charge for remeasurement of contingent consideration liabilities and a £172 million fair value loss on the retained stake in Haleon, contrasting with gains in Q4 2022.
Guidance, Outlook, and Risks
2024 Guidance (CER, ex COVID)
- Turnover: Expected to increase 5% to 7%.
- Adjusted Operating Profit: Expected to increase 7% to 10%.
- Adjusted EPS: Expected to increase 6% to 9%.
- Dividends: Q4 2023 dividend declared at 16p; Full Year 2023 expected at 58p; 2024 expected at 60p.
Long-Term Outlook Upgrade
- 2021-2026 CAGR: Sales upgraded to >7% (from >5%); Adjusted Operating Profit upgraded to >11% (from >10%).
- 2031 Sales: Upgraded to >£38 billion (risk-adjusted, CER).
- Margin Stability: Management expects operating margins to remain broadly stable through the loss of exclusivity for dolutegravir (expected 2028-2030), supported by portfolio transition to long-acting HIV therapies and higher-margin vaccines.
Risks and Contingencies
- Legal Proceedings: Ongoing Zantac litigation; aggregate provision for legal disputes was £0.3 billion as of Dec 31, 2023. GSK cannot meaningfully assess ultimate liability.
- Patent Expiry: Loss of exclusivity for dolutegravir in the US and EU between 2028-2030.
- Contingent Consideration: Significant volatility in fair value of liabilities related to ViiV Healthcare (Shionogi) and Novartis acquisitions.
- Acquisitions: Proposed acquisition of Aiolos Bio (respiratory) and recent acquisition of Bellus Health (camlipixant) carry integration and regulatory risks.
Investor Verification Checklist
- Adjusted vs. Total Results: Verify the reconciliation between Total and Adjusted results, specifically the £1.18 billion in adjusting items for Q4 2023 (contingent consideration and Haleon fair value losses).
- COVID-19 Impact: Confirm the exclusion of COVID-19 solutions (Xevudy, pandemic vaccines) from growth metrics and guidance to understand organic performance.
- Dividend Sustainability: Review the 40-60% payout ratio policy against the projected 2024 dividend of 60p and free cash flow generation.
- Pipeline Milestones: Monitor upcoming Phase III data readouts for depemokimab (asthma), gepotidacin (UTIs/gonorrhoea), and Jemperli (endometrial cancer) in 2024.
- Legal Provisions: Track updates on Zantac litigation provisions and potential indemnification claims.